]>
IRCT20191101045301N1 IRCT 2020-02-12 Esfahan University of Medical Sciences Comparison the effect of Single Dose versus Divided Dose of ASA on endothelial function in diabetic patients (Type2): A Randomized Clinical Trial Comparison the effect of Single Dose (80 mg, Daily) versus Divided Dose (80 mg, BID) of Acetylsalicylic Acid on endothelial function in diabetic patients (Type2): A Randomized Clinical Trial 2020-02-20 anticipated 40 Complete https://irct.ir/trial/44249 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: Simple randomization by Random Allocation Software. 3 Newly diagnosed Diabetes mellitus without complication. Intervention 1: Intervention group: Tab ASA, 80 mg, BID, PO (Osve Company, Iran). Intervention 2: Control group: Tab ASA, 80 mg, daily, PO (Osve Company, Iran). Yes - There is a plan to make this available What will be shared: All data will share after removing patients' identification data. When: Simultaneously with publishing the results To whom: to receive data, researchers need to send request. Conditions: to use in a meta-analysis Where to obtain: Sending email to Zahra Teimouri-jervekani Email address: zari.t.j@gmail.com How to obtain: Formal request from the institute/university is needed to receive data. Contact and personal information are needed. Comments:
public Zahra Teimouri-jervekani
Cardiology department office, Chamran Hospital, Salman Farsi St., Isfahan
Isfahan Iran (Islamic Republic of) 8158388994 +98 31 3261 1406 zari.t.j@gmail.com Esfahan University of Medical Sciences scientific Zahra Teimouri-jervekani
Cardiology department office, Chamran Hospital, Salman Farsi St., Isfahan
Isfahan Iran (Islamic Republic of) 8158388994 +98 31 3261 1406 zari.t.j@gmail.com Esfahan University of Medical Sciences Iran (Islamic Republic of) Age more than 40 year Diabetes Melitus ASCVD Score more than 7.5 40 years no limit Both Any cardiovascular disease Any cerebrovascular disease Any cardiac arrhythmia Any anti platelet or anticoagulant consumption Suffering from acute or chronic infection Platelet disturbance or bleeding tendency NSAIDs consumption in recent 14 days Platelet count less than 120000 Smoking Chronic Kidney Disease (CKD) GI Bleeding Pregnancy E11.9 Type 2 diabetes mellitus without complications Treatment - Drugs Treatment - Drugs Intervention group: Tab ASA, 80 mg, BID, PO (Osve Company, Iran) Control group: Tab ASA, 80 mg, daily, PO (Osve Company, Iran) Flow Mediated Dilation. Timepoint: Bse line, 1 hour after treatment,6 days after treatment( one hour before last dose), 6 days after treatment( one hour after last dose). Method of measurement: Echocardiography. Esfahan University of Medical Sciences Approved 2020-01-04 Iran National Committee for ethics in Biomedical Research 13th floor, Block A, Ministry of Health and Medical Education, Siamye Iran ave. Tehran Tehran Iran (Islamic Republic of)